Future Science Group: RSS News Feed

New Launch - Journal of Comparative Effectiveness Research

Wed, 25 Jan 2012 12:14:18 GMT

Future Medicine Ltd has today announced the launch of the Journal of Comparative Effectiveness Research – a new bimonthly title that provides a rapid-publication platform for debate and for the presentation of new findings in the field of comparative effectiveness research. London-based publishers Future Medicine are part of the Future Science group and are specialists in providing healthcare practitioners and research professionals with high-quality evaluated information.

The goal of comparative effectiveness research is to assist patients, physicians, purchasers, and policy makers to choose between available effective treatments in order to improve healthcare delivery at the level of the individual and on a population scale. The underlying question in undertaking comparative effectiveness research is – which treatment will work best, in which patient, and under what circumstances? Journal of Comparative Effectiveness Research draws upon a variety of disciplinary perspectives to apply scientific principles to one of the pressing challenges of the 21st century.

The editorial direction of Journal of Comparative Effectiveness Research is the responsibility of Senior Editors, Prof. Sheldon Greenfield (University of California, Irvine) and Dr Eugene Rich (Mathematica Policy Research, Washington DC). The Senior Editors are supported by a team of six Associate Editors, together with an Advisory Panel of 40 international experts.

Setting the scene in their introductory Foreword to the launch issue, Prof. Greenfield and Dr Rich state, “Through rigorous evaluation and comprehensive coverage, the Journal of Comparative Effectiveness Research provides stakeholders (including patients, clinicians, payers and health policymakers) with the key data and opinions to make informed and specific decisions relevant to clinical practice.” They comment further, “A broad range of disciplines have relevant methodological expertise and perspectives. Thus, interdisciplinary research must be brought to bear to address these challenging questions. We hope that the Journal of Comparative Effectiveness Research will attract submissions that cross disciplinary lines in ways that other journals may not.”

Elisa Manzotti, Editorial Director at Future Medicine, said, “Comparative effectiveness research has become a major focus for all those involved in healthcare delivery. Ultimately, it is the recipient of care, the patient, who will benefit most from better informed decision making. We are delighted to be working with Prof. Greenfield and Dr Rich to create this new platform for dissemination of topical, concise information and commentary on all aspects of comparative effectiveness research. The journal publishes both original research and reviews, with all submitted articles subjected to rigorous and constructive peer review by at least three independent referees.”

Selected content from the launch issue can be viewed at http://www.futuremedicine.com/toc/cer/1/1. If you are interested in receiving a free 30-day online trial to evaluate the journal’s content please contact info@futuremedicine.com, quoting PRESSCER.

NOTES FOR EDITORS

ABOUT FUTURE SCIENCE GROUP AND FUTURE MEDICINE LTD

Future Medicine Ltd has developed an innovative publishing portfolio to reflect post-genomic medicine. The company is part of the London-based Future Science Group, alongside sister imprints Future Science Ltd and Expert Reviews Ltd. The Future Science Group provides research professionals and clinicians with a unique source of objective, cutting-edge information on exciting emerging trends in science and medicine. Please see www.future-science-group .com and www.futuremedicine.com for more information.

ABOUT JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH

Description

Healthcare is at a turning point. We have entered a new era of high patient expectations, aging populations and socioeconomic constraints. At the same time, attention is focusing more closely on personalized approaches to healthcare delivery, and healthcare options, especially in fields such as oncology, are proliferating. There is now a pressing need to make direct comparisons between the available healthcare options and interventions in order to address uncertainties in optimal clinical practice.

In this new environment, the goal of comparative effectiveness research (CER) is to assist patients, physicians, purchasers, and policy makers to choose between the available effective treatments in order to improve healthcare delivery at the level of the individual and on a population scale. The underlying question in undertaking comparative effectiveness research is - which treatment will work best, in which patient, and under what circumstances?

Against this backdrop, the peer-reviewed bimonthly journal Journal of Comparative Effectiveness Research provides a rapid-publication platform for debate and for the presentation of new findings.

Articles published in Journal of Comparative Effectiveness Research cover key areas such as:

• Studies of effectiveness or comparative effectiveness yielding new findings relating to diagnostics, therapeutics, surgical procedures, or other healthcare services or options
• Systematic reviews of available evidence relating to the pros and cons of healthcare options for specific patient groups including comparative safety
• Perspectives and debate relating to the performance of comparative effectiveness studies and best practice issues
• Commentary on both patient-relevant outcomes and economic implications
• Direct 'head-to-head' comparisons of available diagnostic and therapeutic options - evaluating clinical alternatives with current standard of care
• Clinical trial commentaries - evaluating and interpreting the findings of recently completed CER trials as well as presenting the design and rationale of newly commenced studies
• Pharmacoeconomic studies, health economics and outcomes research

Through rigorous evaluation and comprehensive coverage, Journal of Comparative Effectiveness Research provides stakeholders (including patients, clinicians, healthcare purchasers, and health policy makers) with the key data and opinions to make informed and specific decisions on clinical practice.

Therapy relaunches as Clinical Practice in 2012

Tue, 03 Jan 2012 12:14:18 GMT

New name, new look, new content – Therapy relaunches as Clinical Practice in 2012

Future Medicine Ltd has today announced the rebranding of the journal Therapy (ISSN:1475-0708) under the new name of Clinical Practice (ISSN:2044-9038). The new title is designed to more aptly reflect the needs of the readership and the future direction for the journal. The journal addresses key issues and controversies in modern medicine.

Over the past eight years Therapy has established a solid readership as a general medical title. The journal covers a broad spectrum of medical disorders and reaches out to a wide audience including clinicians, decision-makers, researchers and a range of professionals in the healthcare community. Now, as well as the new name, cover design and page layouts, the relaunched title includes novel article types drawing on expert opinion regarding new approaches to managing and treating disease, identifying clinical burden and unmet needs, as well as analyzing the implications of recently published guidelines for daily practice.

The editorial direction of Clinical Practice is driven by three Editors-in-Chief; Gregory YH Lip (City Hospital, Birmingham, UK), Samy I McFarlane (State University of New York, NY, USA) and James Larkin (Royal Marsden Hospital, London, UK), who coordinate efforts to achieve the highest quality content across the most topical subjects in modern medicine. The wider Editorial Board consists of influential clinicians representative of their respective fields to ensure a good balance of published content and to provide moderation and evaluation during the publication process.

The Editors-in-Chief and publishers are keen to point out that the journal’s high editorial standards will be maintained and nurtured. Elisa Manzotti, Editorial Director of FSG, remarked that, “We are delighted with the new look and direction of Clinical Practice and look forward to working with the Editors-in-Chief, Editorial Board and referees, and our author base of internationally renowned clinicians, to provide a platform for expert opinion, commentary and debate across the full spectrum of modern medicine in the coming years.”

Samy I McFarlane commented that, "Clinical Practice is designed for busy practitioners, intended to put imminently relevant information at their fingertips. This is particularly vital given the increasing workload and the dwindling time for the health care providers to keep up with the plethora of medical information emerging on a daily basis".

The editorial office is now actively soliciting contributions of reviews, perspectives and editorial articles for Clinical Practice. For a full range of the exciting new article types included in Clinical Practice please see our Author Guidelines. If you are interested in contributing any of the article types listed then please contact the Managing Commissioning Editor, Laura McGuinness, on l.mcguinness@futuremedicne.com.

Selected content from the first issue of Clinical Practice can be viewed at www.futuremedicine.com/loi.cpr. If you are interested in receiving a free 30-day online trial to evaluate the journals content please contact info@futuremedicine.com, quoting CPR12PR.

--Ends--
For further information on Clinical Practice, please contact the Victoria Lane, Senior Manager, Future Science Group.
T: +44 (0) 20 8371 6090 E: v.lane@futuremedicine.com

ABOUT CLINICAL PRACTICE

Clinical Practice provides a forum to address all aspects facing clinical practitioners today, from exploring unmet therapeutic needs to analyzing the implications of real-world evidence, applications of clinical guidelines and multidisciplinary approaches to care.

Editors in Chief
Samy I McFarlane, State University of New York, NY, USA
Gregory YH Lip, City Hospital, Birmingham, UK
James Larkin, Royal Marsden Hospital, London, UK
Topics include:
• Application of Phase III clinical trial results in clinical practice
• Findings from Phase IV/post-marketing studies
• Understanding of unmet clinical needs and therapeutic burden
• Practical approaches to disease management
• Evidence-based treatment guidelines
• Personal perspectives in treating a disease
• Multidisciplinary team approaches to care
Articles are subject to peer-review by three independent referees on a double-blind basis. Authors publishing in the journal are asked to disclose any professional or financial interest that may be perceived as causing a conflict of interest in the context of the article.

ABOUT FUTURE SCIENCE GROUP AND FUTURE MEDICINE LTD

Future Science Group, based in London has developed an innovative publishing portfolio to reflect post-genomic medicine. The sequencing of the human genome was a colossal milestone in the evolution of healthcare, with repercussions for all those involved in the healthcare chain.
Through its imprints, Future Medicine Ltd and Expert Reviews Ltd, Future Science Group provides healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in the light of these advances. For more information please access www.futuremedicine.com.